Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

287.63USD
3:59pm EST
Change (% chg)

$0.73 (+0.25%)
Prev Close
$286.90
Open
$287.75
Day's High
$289.43
Day's Low
$285.36
Volume
399,658
Avg. Vol
581,937
52-wk High
$333.24
52-wk Low
$223.03

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $61,956.61
Shares Outstanding(Mil.): 215.95
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 16.96 28.45 29.35
EPS (TTM): 16.91 -- --
ROI: 20.31 13.47 12.97
ROE: 34.42 14.36 14.11

BRIEF-Forward Pharma receives $1.25 bln pursuant to settlement and license agreement with Biogen

* Forward Pharma received US$ 1.25 bln pursuant to settlement and license agreement with Biogen

Feb 09 2017

BRIEF-Forward Pharma enters license agreement with 2 units of Biogen and other parties

* Approved entry into settlement, license agreement with 2 wholly owned subsidiaries of Biogen Inc and certain other parties

Feb 01 2017

BRIEF-Biogen completes separation of global hemophilia business, Bioverativ

* Biogen completes separation of global hemophilia business, bioverativ Source text for Eikon: Further company coverage:

Feb 01 2017

Biogen sees gradual Spinraza launch, eyes mid-year EU approval

Biogen Inc said on Thursday that the first U.S. patients have received its new drug for the leading genetic cause of death in infants and that it anticipates mid-year approval of Spinraza in the European Union.

Jan 26 2017

UPDATE 3-Biogen sees gradual Spinraza launch, eyes mid-year EU approval

Jan 26 Biogen Inc said on Thursday that the first U.S. patients have received its new drug for the leading genetic cause of death in infants and that it anticipates mid-year approval of Spinraza in the European Union.

Jan 26 2017

BRIEF-Biogen Phase III Alzheimer's trial enrollment ahead of expectations

* Biogen CEO says enrolling of patients for phase III aducanumab Alzheimer's trial ahead of company expectations

Jan 26 2017

Biogen profit drops 22 pct due to Tecfidera-related costs

Jan 26 Biogen Inc reported a near 22 percent fall in fourth-quarter income, hurt by higher costs related to its top-selling multiple sclerosis drug, Tecfidera.

Jan 26 2017

Possible liver injury added to label of Biogen MS drug

The prescribing label for Biogen Inc's big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury that could require hospitalization, the company said on Wednesday.

Jan 25 2017

Possible liver injury added to label of Biogen MS drug

Jan 25 The prescribing label for Biogen Inc's big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury that could require hospitalization, the company said on Wednesday.

Jan 25 2017

BRIEF-Ewopharma partners with Biogen to commercialise Benepali and Flixabi

* Ewopharma partners with biogen to commercialise benepali and flixabi in central eastern europe

Jan 23 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $119.52 -0.14
Pfizer Inc. (PFE.N) $33.59 -0.03
Novartis AG (NOVN.S) CHF77.80 +0.40
Merck & Co., Inc. (MRK.N) $65.29 -0.19
Roche Holding Ltd. (ROG.S) CHF246.30 -0.20
Roche Holding Ltd. (RO.S) CHF249.90 +0.30
Bayer AG (BAYGn.DE) €107.90 -1.00
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €80.27 -0.26
GlaxoSmithKline plc (GSK.L) 1,653.50 +8.00

Earnings vs. Estimates